LTR Pharma (ASX:LTP) Full Year 2025 Results

Key Financial Results

Net loss: AU$5.59m (loss narrowed by 20% from FY 2024).

AU$3.34 loss per share.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

ASX:LTP Earnings and Revenue History August 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

LTR Pharma shares are down 9.3% from a week ago.

Risk Analysis

We don’t want to rain on the parade too much, but we did also find 5 warning signs for LTR Pharma (1 doesn’t sit too well with us!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.